From October 1, 2023 to December 31, 2023, the company has repurchased 5,332,769 shares, representing 3.93% for $34.65 million. With this, the company has completed the repurchase of 6,613,780 shares, representing 4.87% for $44.05 million under the buyback announced on May 19, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 USD | +1.61% | +1.29% | -30.92% |
May. 08 | Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 Revenue $44.9M, vs. Street Est of $43.6M | MT |
May. 08 | Transcript : Cytek Biosciences, Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.92% | 827M | |
+11.73% | 226B | |
+9.53% | 188B | |
+14.63% | 137B | |
+27.47% | 108B | |
-0.04% | 63.19B | |
+13.73% | 52.26B | |
+4.86% | 51B | |
+7.72% | 43.89B | |
+7.86% | 38.07B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Tranche Update on Cytek Biosciences, Inc.'s Equity Buyback Plan announced on May 19, 2023.